The Biostatistics Shared Resource provides support for the three broad major programmatic areas of YCC: clinical science;basic science;and population science. The services provided include: biostatistical support to research projects, assistance with the statistical and research aspects of new research projects and grant applications, data analysis, and training/As such, this core is vital to clinical trials/study design process. Additionally, this core has the major responsibility to support the protocol review and monitoring process of the YCC. Thus, this Shared Resource provides critical support for the complete spectrum of statistical services, from study design through the final research report writing. In late 2005, Dr. Theodore Holford accepted the position as Director of this core facility. Dr. Holford will work closely with Dr. Daniel Zelterman, who serves as Co-Director of the Biostatistics Shared Resource. The Biostatistics Shared Resource is Cancer Center Managed and provides statistical support and data analysis to YCC in the form of active consultation with six Ph.D. statisticians dedicated to the YCC. The 2 major criticisms of the previous renewal have been addressed. Specifically, creation of a Biostatistics Clinical Studies Group, chaired by Dr. Holford, ensures that biostatistical expertise applied to Protocol Review Committee evaluation of prospective clinical trials will be completely distinct from that involved in the particular study's design and subsequent analysis of accrued data. In addition, the biostatistical staff has been significantly expanded, to provide full coverage for the marked increase in investigator-initiated clinical research activities, resulting from the recruitment of a large number of new clinical researchers. Over the past 2 years, 11 new investigative clinical oncologists have joined the YCC, and their clinical trials efforts have led to a 56% increase in the required biostatistical support. In order to support these increased needs, the faculty biostatistician staff of this Shared Resource has grown from 2 to 7. In this renewal application, we are requesting 1.75 FTE for the next period of funding. In 2005 100%, or 42, users were YCC members (65.5% Peer reviewed) from all 8 of the YCC research programs

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-31
Application #
7916706
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
31
Fiscal Year
2009
Total Cost
$140,993
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331
De Feyter, Henk M; Behar, Kevin L; Corbin, Zachary A et al. (2018) Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv 4:eaat7314
Ventura, Alessandra; Vassall, Aaron; Robinson, Eve et al. (2018) Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res 78:4045-4058
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :

Showing the most recent 10 out of 675 publications